MARKET

CLVS

CLVS

Clovis Oncology Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7133
-0.0268
-3.62%
After Hours: 0.7300 +0.0167 +2.34% 18:52 05/19 EDT
OPEN
0.7500
PREV CLOSE
0.7401
HIGH
0.7600
LOW
0.6948
VOLUME
3.66M
TURNOVER
0
52 WEEK HIGH
7.24
52 WEEK LOW
0.6948
MARKET CAP
102.63M
P/E (TTM)
-0.3385
1D
5D
1M
3M
1Y
5Y
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 807 companies reached new 52-week lows.
Benzinga · 05/11 16:28
Alcon (ALC) to Report Q1 Earnings: What's in the Cards?
Strength in Vision Care with the addition of new products and recent acquisition is likely to have contributed to Alcon's (ALC) first-quarter performance.
Zacks · 05/09 15:05
92 Biggest Movers From Friday
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the commercialization of space technologies and services.
Benzinga · 05/09 10:27
Endo (ENDP) Beats on Q1 Earnings, Guides Weak Q2 Results
Endo (ENDP) tops Q1 earnings and sales estimates. However, Vasostrict faces generic competition and the guidance for Q2 is dismal.
Zacks · 05/06 17:23
Clovis Oncology downgraded to neutral at Wainwright on Rubraca ovarian cancer uncertainty
H.C. Wainwright has downgraded Clovis Oncology (NASDAQ:CLVS) to neutral from buy over concerns about a potential launch of Rubraca (rucaparib) as a first-line ovarian cancer treatment. Shares are down 30% in Friday
Seekingalpha · 05/06 16:34
Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues Lag
Global Blood Therapeutics (GBT) reports y/y wider loss in Q1. Revenues witness a rise.
Zacks · 05/05 14:22
Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference
BOULDER, Colo., May 05, 2022--Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference
Business Wire · 05/05 12:00
Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss
Clovis (CLVS) incurs wider-than-estimated loss for first-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.
Zacks · 05/04 18:21
More
No Data
Learn about the latest financial forecast of CLVS. Analyze the recent business situations of Clovis Oncology Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
66.67%Hold
33.33%Under-perform
0.00%Sell
Analyst Price Target
The average CLVS stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.
High3.000
Average3.000
Low3.000
Current 0.7133
EPS
Actual
Estimate
-0.49-0.37-0.24-0.12
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 266
Institutional Holdings: 74.36M
% Owned: 51.68%
Shares Outstanding: 143.88M
TypeInstitutionsShares
Increased
53
7.37M
New
25
2.02M
Decreased
40
4.39M
Sold Out
26
645.46K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.00%
Pharmaceuticals & Medical Research
+0.51%
Key Executives
Non-Executive Chairman/Independent Director
Ginger Graham
President/Chief Executive Officer/Co-Founder/Director
Patrick Mahaffy
Co-Founder/Executive Vice President
Gillian Ivers - Read
Chief Financial Officer/Executive Vice President
Daniel Muehl
Executive Vice President/Chief Scientific Officer
Thomas Harding
Executive Vice President/General Counsel
Paul Gross
Executive Vice President/Director of Human Resources
Ann Bozeman
Executive Vice President
Lindsey Rolfe
Independent Director
Brian Atwood
Independent Director
Robert Azelby
Independent Director
James Blair
Independent Director
Richard Fair
Independent Director
Keith Flaherty
Independent Director
Paul Klingenstein
Independent Director
Edward Mckinley
Independent Director
Ronit Simantov
Independent Director
Thorlef Spickschen
No Data
No Data
About CLVS
Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and other international markets. The Company operates through two geographic segments: U.S. and ex-U.S. The Company’s product Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor which inhibits vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3). Its other product includes FAP-2286, which is a clinical candidate under investigation as a peptide-targeted radionuclide therapy (PTRT).

Webull offers kinds of Clovis Oncology Inc stock information, including NASDAQ:CLVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLVS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLVS stock methods without spending real money on the virtual paper trading platform.